Real-time Treatment of Chronic Pain Using Digital Intelligence

Change in the SF-36 Physical Functioning domain score from baseline to Week 2 and Week 4.

Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the Physical Functioning domain score (range 0-100; higher scores indicate better functioning) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in the SF-36 Physical Limitations domain score over time, measured at baseline, Week 2, and Week 4.

Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the Physical Limitations domain score (range 0-100; higher scores indicate fewer physical limitations) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in the SF-36 Emotional Limitations domain score over time, measured at baseline, Week 2, and Week 4.

Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the Emotional Limitations domain score (range 0-100; higher scores indicate fewer emotional limitations) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in the SF-36 Energy and Vitality domain score over time, measured at baseline, Week 2, and Week 4

Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the Energy and Vitality domain score (range 0-100; higher scores indicate greater energy and vitality) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in the SF-36 Psychological Health domain score over time, measured at baseline, Week 2, and Week 4.

Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the Psychological Health domain score (range 0-100; higher scores indicate better psychological well-being) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in the SF-36 Social Functioning domain score over time, measured at baseline, Week 2, and Week 4

Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the Social Functioning domain score (range 0-100; higher scores indicate better social functioning) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in the SF-36 Physical Pain domain score over time, measured at baseline, Week 2, and Week 4

Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the Physical Pain domain score (range 0-100; higher scores indicate less pain) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in the SF-36 General Health domain score from baseline to Week 2 and Week 4.

Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the General Health domain score (range 0-100; higher scores indicate better perceived health) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in Oswestry Disability Index (ODI) 2.1a total score from baseline to Week 2 and Week 4

Disability related to low back pain is assessed using the Croatian-validated version of the Oswestry Disability Index (ODI) 2.1a questionnaire. The outcome represents the change in the total ODI score (range 0-100; higher scores indicate greater disability) measured at baseline, Week 2, and Week 4. Greater decreases in score indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in Depression score measured by the Depression Anxiety Stress Scales-21 (DASS-21) from baseline to Week 2 and Week 4

Symptoms of depression are assessed using the Croatian-validated version of the Depression Anxiety Stress Scales-21 (DASS-21). The outcome represents the change in the Depression subscale score measured at baseline, Week 2, and Week 4. Higher scores indicate more severe depressive symptoms, and greater decreases in score indicate clinical improvement.

Time frame: baseline to Week 2 and Week 4

Change in Anxiety score measured by the Depression Anxiety Stress Scales-21 (DASS-21) from baseline to Week 2 and Week 4

Symptoms of anxiety are assessed using the Croatian-validated version of the Depression Anxiety Stress Scales-21 (DASS-21). The outcome represents the change in the Anxiety subscale score measured at baseline, Week 2, and Week 4. Higher scores indicate more severe anxiety symptoms, and greater decreases in score indicate clinical improvement.

Time frame: baseline to Week 2 and Week 4

Change in Stress score measured by the Depression Anxiety Stress Scales-21 (DASS-21) from baseline to Week 2 and Week 4

Stress symptoms are assessed using the Croatian-validated version of the Depression Anxiety Stress Scales-21 (DASS-21). The outcome represents the change in the Stress subscale score measured at baseline, Week 2, and Week 4. Higher scores indicate more severe stress symptoms, and greater decreases in score indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in Subjective Sleep Quality score measured by the Pittsburgh Sleep Quality Index (PSQI) from baseline to Week 2 and Week 4

Sleep quality is assessed using the Pittsburgh Sleep Quality Index (PSQI). The outcome represents the change in the Subjective Sleep Quality component score measured at baseline, Week 2, and Week 4. Higher scores indicate worse sleep quality, and greater decreases in score indicate clinical improvement.

Time frame: baseline to Week 2 and Week 4

Change in Sleep Latency score measured by the PSQI from baseline to Week 2 and Week 4

Sleep latency is assessed using the Pittsburgh Sleep Quality Index (PSQI). The outcome represents the change in the Sleep Latency component score measured at baseline, Week 2, and Week 4. Higher scores indicate longer time to fall asleep and worse sleep, and greater decreases indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4.

Change in Sleep Duration score measured by the PSQI from baseline to Week 2 and Week 4

Sleep duration is assessed using the PSQI. The outcome represents the change in the Sleep Duration component score measured at baseline, Week 2, and Week 4. Higher scores indicate shorter sleep duration and worse sleep, and greater decreases indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in Habitual Sleep Efficiency score measured by the PSQI from baseline to Week 2 and Week 4

Habitual Sleep Efficiency is assessed using the PSQI. The outcome represents the change in the Habitual Sleep Efficiency component score measured at baseline, Week 2, and Week 4. Higher scores indicate lower sleep efficiency and worse sleep, and greater decreases indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in Sleep Disturbances score measured by the PSQI from baseline to Week 2 and Week 4

Sleep Disturbances are assessed using the PSQI. The outcome represents the change in the Sleep Disturbances component score measured at baseline, Week 2, and Week 4. Higher scores indicate more frequent disturbances and worse sleep, and greater decreases indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4.

Change in Use of Sleeping Medication score measured by the PSQI from baseline to Week 2 and Week 4

Use of Sleeping Medication is assessed using the PSQI. The outcome represents the change in the Use of Sleeping Medication component score measured at baseline, Week 2, and Week 4. Higher scores indicate more frequent medication use, and greater decreases indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in Daytime Dysfunction score measured by the PSQI from baseline to Week 2 and Week 4

Daytime Dysfunction is assessed using the PSQI. The outcome represents the change in the Daytime Dysfunction component score measured at baseline, Week 2, and Week 4. Higher scores indicate greater daytime impairment, and greater decreases indicate clinical improvement.

Time frame: baseline to Week 2 and Week 4

Physical activity (step count) measured by Apple Watch at baseline, Week 2, and Week 4

Physical activity (step count) is measured using the Apple Watch wearable device. The outcome represents the average daily step count recorded and summarized for the assessment periods at baseline, Week 2, and Week 4. Higher values indicate greater physical activity.

Time frame: baseline, Week 2, and Week 4

Sleep quality (Sleep Score) measured by Apple Watch at baseline, Week 2, and Week 4

Sleep quality (Sleep Score) is measured using sleep analysis data generated from sleep stage tracking recorded by the Apple Watch wearable device. The outcome represents the Sleep Score assessed and summarized at baseline, Week 2, and Week 4. Higher scores indicate better sleep quality.

Time frame: baseline, Week 2, and Week 4.

Change in PCS Rumination subscale score from baseline to Week 2 and Week 4

Pain rumination is assessed using the Rumination subscale of the Pain Catastrophizing Scale (PCS), a validated self-report questionnaire measuring repetitive negative focus on pain. The outcome represents the change in the PCS Rumination subscale score measured at baseline, Week 2, and Week 4. Higher scores indicate greater rumination, and greater decreases indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in PCS Magnification subscale score from baseline to Week 2 and Week 4

Pain magnification is assessed using the Magnification subscale of the Pain Catastrophizing Scale (PCS). The outcome represents the change in the PCS Magnification subscale score measured at baseline, Week 2, and Week 4. Higher scores indicate greater magnification of pain, and greater decreases indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in PCS Helplessness subscale score from baseline to Week 2 and Week 4

Pain-related helplessness is assessed using the Helplessness subscale of the Pain Catastrophizing Scale (PCS), a validated self-report questionnaire measuring perceived inability to cope with pain. The outcome represents the change in the PCS Helplessness subscale score measured at baseline, Week 2, and Week 4. Higher scores indicate greater helplessness, and greater decreases indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in PCS total score from baseline to Week 2 and Week 4

Pain catastrophizing is assessed using the total score of the Pain Catastrophizing Scale (PCS). The outcome represents the change in the PCS total score measured at baseline, Week 2, and Week 4. Higher scores indicate greater pain catastrophizing, and greater decreases indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in painDETECT questionnaire total score from baseline to Week 2 and Week 4

Neuropathic pain features are assessed using the painDETECT questionnaire, a validated self-report screening instrument designed to identify neuropathic pain components. The outcome represents the change in the painDETECT total score measured at baseline, Week 2, and Week 4. Higher scores indicate a greater likelihood of neuropathic pain, and greater decreases indicate clinical improvement.

Time frame: baseline, Week 2, and Week 4

Change in anxiety symptoms measured by the Hospital Anxiety and Depression Scale - Anxiety subscale (HADS-A).

Anxiety symptoms assessed using the Hospital Anxiety and Depression Scale (HADS). The anxiety subscale (HADS-A) consists of 7 items, each scored from 0 to 3, with total scores ranging from 0 to 21. Higher scores indicate greater anxiety symptom severity.

Time frame: Baseline, Week 2, and Week 4.

Change in depressive symptoms measured by the Hospital Anxiety and Depression Scale - Depression subscale (HADS-D).

Depressive symptoms assessed using the Hospital Anxiety and Depression Scale (HADS). The depression subscale (HADS-D) consists of 7 items, each scored from 0 to 3, with total scores ranging from 0 to 21. Higher scores indicate greater depressive symptom severity.

Time frame: Baseline, Week 2, and Week 4.

Change in neck-related disability measured by the Neck Disability Index (NDI).

Neck-related disability assessed using the Neck Disability Index (NDI), a 10-item patient- reported questionnaire evaluating the impact of neck pain on daily activities. Each item is scored from 0 to 5, with total scores ranging from 0 to 50. Higher scores indicate greater neck- related disability.

Time frame: Baseline, Week 2, and Week 4.

Beliefs about the necessity of medication measured by the Beliefs about Medicines Questionnaire - Specific Necessity subscale (BMQ-Specific Necessity) at Baseline, Week 2, and Week 4.

Beliefs about the personal necessity of prescribed medication assessed using the Beliefs about Medicines Questionnaire (BMQ) at Baseline, Week 2, and Week 4. The BMQ-Specific Necessity subscale consists of 5 items evaluating patients' beliefs about the need for their medication to maintain health and control illness. Each item is rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree), with total scores ranging from 5 to 25. Higher scores indicate stronger beliefs in the necessity of medication.

Time frame: Baseline, Week 2, and Week 4.

Concerns about medication measured by the Beliefs about Medicines Questionnaire - Specific Concerns subscale (BMQ-Specific Concerns) at Baseline, Week 2, and Week 4.

Concerns about prescribed medication assessed using the Beliefs about Medicines Questionnaire (BMQ) at Baseline, Week 2, and Week 4. The BMQ-Specific Concerns subscale consists of 5 items evaluating patients' worries about potential adverse effects and long-term consequences of medication. Each item is rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree), with total scores ranging from 5 to 25. Higher scores indicate greater concerns about medication.

Time frame: Baseline, Week 2, and Week 4.